Global Pharmaceutical Leader

Advancing the Biology of Potential.

Harnessing generative biotechnology and molecular intelligence to solve the world's most complex healthcare challenges.

$248B Market Capitalization
42 Phase III Programs
12.4% R&D Revenue Allocation
85+ Global Markets

Precision Medicine, At Scale.

Our AI-native R&D engine accelerates drug discovery from years to months, identifying high-affinity molecules with unprecedented precision.

Neural-Proteomics

Decoding protein interactions through high-fidelity neural network modeling to target previously "undruggable" pathologies.

Synthetic Genomics

Engineering programmable RNA therapeutics that respond dynamically to cellular environments.

Clinical Digital Twins

Simulating patient response profiles to optimize clinical trial outcomes and patient safety protocols.

Active Development Portfolio

Full Pipeline Report (PDF)

SY-402 (Oncology)

Next-gen CAR-T Cell Therapy

SY-109 (Neurology)

Amyloid Plaque Inhibitor

SY-882 (Immunology)

Monoclonal Antibody

A Global Standard for Trust.

Operating with absolute integrity across 85 countries. Our governance framework exceeds FDA, EMA, and PMDA requirements, ensuring global health equity and patient safety.

Net Zero 2035

Committed to carbon-neutral manufacturing across all facilities.

ESG AA Rating

Top-tier environmental and social governance performance.